Uveitis Treatment Market – By Treatment Type, By Disease Type, By Route of Administration, By Disease Etiology, By Distribution Channel - Global Forecast, 2025 – 2034

Uveitis Treatment Market Size

The global uveitis treatment market size was valued at around USD 768.5 million in 2024 and is estimated to grow at 6.6% CAGR from 2025 to 2034. The increasing prevalence of autoimmune conditions such as rheumatoid arthritis, lupus, and Crohn's disease is contributing to a rise in uveitis cases, particularly the non-infectious types. Uveitis accounts for 10%–15% of blindness cases in the U.S., with annual costs estimated at approximately USD 242 million, according to the NIH.
 

Moreover, the aging global population is expected to result in a higher incidence of age-related eye disorders, including uveitis. The WHO projects that the population aged 60 and over will grow from 900 million in 2015 to 2 billion by 2050, thereby expanding the patient pool and increasing the demand for uveitis treatments.
 

Innovations in treatment delivery systems and regulatory approvals are improving both treatment outcomes and convenience. For example, in October 2021, the FDA approved XIPERETM (triamcinolone acetonide injectable suspension) for macular edema associated with uveitis. Advanced therapies and delivery methods are addressing unmet medical needs, attracting healthcare providers and patients, and driving market growth.
 

Uveitis treatment involves managing inflammation in the uvea, the middle layer of the eye. This condition can affect one or both eyes and may be caused by infections, autoimmune diseases, or other inflammatory disorders. If left untreated, uveitis can lead to severe complications such as vision loss, cataracts, or glaucoma.
 

Uveitis Treatment Market Trends

• Long-acting injectable treatments, such as depot steroid injections and biologic therapies, are becoming increasingly important in the management of uveitis. These treatments help reduce the risk of legal blindness, decrease the frequency of dosing and clinic visits, and enhance patient adherence and convenience.
   
• For example, the International Agency for the Prevention of Blindness reports that uveitis is responsible for an estimated 30,000 new cases of legal blindness in the U.S. annually, emphasizing the need for effective treatment options. The development of long-acting therapies is expected to significantly contribute to market growth by addressing the challenges of treatment adherence and improving patient comfort.
   
• Furthermore, combination therapies are being used more frequently, especially for chronic or hard-to-manage cases of uveitis. These therapies typically combine corticosteroids with immunosuppressive agents or biologics, aiming to increase treatment effectiveness while minimizing the side effects associated with prolonged steroid use. The growing adoption of combination therapies is expected to drive market expansion by providing more effective and personalized treatment options for patients with complex uveitis cases.
   

Uveitis Treatment Market Analysis

Based on treatment type, the market is segmented into corticosteroids, immunosuppressants/Immunomodulators, biologics, cycloplegic agents, analgesics, and other treatments. The corticosteroids segment dominated the market with the largest revenue share of 37.3% in 2024.
 

• Corticosteroids are the primary treatment for many uveitis patients due to their effectiveness in controlling inflammation. These medications rapidly reduce inflammation and alleviate symptoms such as pain, redness, and blurred vision, making them essential for treating both acute and chronic forms of uveitis.
   
• The ongoing management of chronic uveitis cases with corticosteroids ensures a consistent demand for these medications. Additionally, corticosteroids play a critical role in preventing complications associated with long-term inflammation, such as cataracts and glaucoma, further supporting their continued use in uveitis treatment.
   

Based on disease type, the uveitis treatment market is segmented into anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis. The anterior uveitis segment dominated the market with the largest revenue of USD 424.6 million in 2024.
 

• Anterior uveitis, the most common form of the disease, accounts for 40% to 50% of all uveitis cases. Its high prevalence, especially among younger adults, creates significant demand for effective treatments. This demand directly influences the need for a range of medications and therapies, including corticosteroids and immunosuppressive drugs, which are integral to standard care protocols.
   
• The market benefits from a variety of treatment options, including topical corticosteroids, oral corticosteroids, and nonsteroidal anti-inflammatory drugs (NSAIDs). This flexibility enables physicians to tailor treatments based on the severity of the condition, leading to improved patient outcomes and market growth. The ongoing development of advanced therapies, such as biologics, is expected to further expand the market in the future.
   

Based on route of administration, the uveitis treatment market is segmented into oral, topical, and injectable. The topical segment dominated the market with the largest revenue of USD 413.7 million in 2024.
 

• Topical corticosteroids and NSAID eye drops are preferred for uveitis treatment due to their localized application. This method minimizes systemic side effects typically associated with oral medications. The localized approach is especially beneficial for uveitis patients who require long-term management to control flare-ups.
   
• In addition to their targeted efficacy, topical treatments for uveitis, specifically corticosteroids and NSAIDs, are generally more cost-effective than systemic therapies, such as oral corticosteroids, biologics, and immunosuppressants. The lower cost of topical treatments makes them an attractive option, particularly in regions with healthcare budget constraints.
   

Based on disease etiology, the uveitis treatment market is bifurcated into infectious and non-infectious. The non-infectious segment dominated the market with the largest revenue of USD 558.2 million in 2024.
 

• Non-infectious uveitis is often linked to autoimmune conditions such as rheumatoid arthritis, sarcoidosis, ankylosing spondylitis, and inflammatory bowel disease. The increasing prevalence of these autoimmune disorders, particularly in developed countries, leads to a rise in non-infectious uveitis cases.
   
• According to the World Health Organization (WHO), the global prevalence of rheumatoid arthritis is estimated at 1%, affecting approximately 14 million people worldwide. This growing prevalence of autoimmune diseases is a key factor driving the expansion of the non-infectious market.
   
• Furthermore, advances in immunosuppressive therapies (such as methotrexate, azathioprine, and cyclophosphamide) and biologic drugs (like TNF inhibitors and IL inhibitors) have introduced more effective options for managing non-infectious uveitis, particularly in cases that are resistant to corticosteroids.
   
• These advanced therapies target specific immune pathways involved in inflammation, offering improved control with fewer side effects.
   

Based on distribution channel, the uveitis treatment market is segmented into hospital pharmacies, retail pharmacies, e-commerce, and other distribution channels. The hospital pharmacies segment dominated the market with the largest revenue of USD 329.1 million in 2024.
 

• The increasing adoption of biologics and immunosuppressive therapies is driving growth in hospital pharmacies. These treatments often require specialized administration, such as intravenous infusions or injections, along with close monitoring for potential side effects. As a result, hospital pharmacies are playing an increasingly significant role in the distribution and management of these therapies.
   
• Additionally, hospitals are investing in advanced infrastructure to better serve patients with chronic and complex conditions, including uveitis. This investment includes expanding pharmacy services to accommodate specialized treatments, manage immunosuppressive therapies, and effectively handle biologic drugs.
   

The U.S. uveitis treatment market is projected to grow significantly, reaching USD 612.2 million by 2034.
 

• The rising prevalence of uveitis in the U.S. population is driving demand for effective treatment options. For example, a study by the American Academy of Ophthalmology found that the prevalence of uveitis in the U.S. from 2013 to 2023 was 285 cases per 100,000 people.
   
• Additionally, the U.S. Food and Drug Administration (FDA) regulates and approves new therapies for uveitis, including biologic drugs, immunosuppressive agents, and topical corticosteroids. The FDA's approval process ensures that safe and effective treatments reach the U.S. market, promoting the adoption of new therapies by healthcare providers.
   

The uveitis treatment market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The increasing incidence of autoimmune disorders in the UK is contributing to a rise in uveitis cases, which in turn drives the demand for effective treatments, including immunosuppressive therapies and biologic drugs. According to the National Health Service (NHS), approximately 2 to 5 in every 10,000 people in the UK are affected by uveitis each year. This prevalence highlights the need for advanced treatments, supporting growth in the uveitis therapeutics market.
   
• Moreover, the NHS provides extensive access to uveitis treatments, offering specialist care to a broad segment of the population. For instance, the UK government’s commitment to improving eye care services, outlined in the NHS Long Term Plan, includes increased funding for specialized ophthalmic services. This initiative aims to reduce waiting times and enhance access to treatments for conditions like uveitis, further stimulating market growth in the coming years.
   

Japan uveitis treatment market is anticipated to witness lucrative growth between 2025 – 2034.
 

• According to the World Health Organization (WHO), in 2023, the average life expectancy in Japan was 87.14 years for women and 81.09 years for men, among the highest globally. This longevity has contributed to a rapidly aging population, with 29.1% of Japanese citizens aged 65 or older in 2023, as reported by the BBC.
   
• Given the higher risk of developing age-related eye conditions, including uveitis and age-related macular degeneration, the demand for treatments to ensure proper eye care is on the rise. This demographic shift is expected to continue driving market growth in Japan.
   

The uveitis treatment market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Saudi Arabia is significantly expanding its healthcare infrastructure, placing increased focus on ophthalmology and autoimmune diseases. The country is seeing an increase in uveitis centers and ophthalmology clinics that provide comprehensive care for uveitis patients. This expansion of healthcare facilities and specialized care centers, particularly in urban areas, is driving the adoption of advanced uveitis treatments in Saudi Arabia.
   

Uveitis Treatment Market Share

The market is competitive, featuring both major global companies and numerous smaller firms. A key strategy for participants is investing in the development of advanced uveitis treatments, such as targeted biologic therapies, ocular corticosteroid implants, and gene therapy, to enhance treatment efficiency. Strategic partnerships with research institutions and healthcare providers are crucial for integrating modern technologies and expanding distribution, enabling companies to address the rising demand for non-invasive and cost-effective diagnostic solutions. Regulatory support and streamlined approval processes further drive innovation and market entry, solidifying the position of firms within the growing market.
 

Uveitis Treatment Industry News:

• In September 2024, Priovant Therapeutics announced that its brepocitinib had been granted Fast Track Designation by the FDA for the treatment of non-infectious uveitis. The Fast Track process is designed to expedite the development and review of drugs intended to treat serious conditions and address unmet medical needs. This designation offers significant benefits to Priovant Therapeutics, including accelerated development timelines, enhanced communication with the FDA, and the potential for a faster market entry.
• In June 2024, ANI Pharmaceuticals announced the acquisition of Alimera Sciences. Through this acquisition, ANI Pharmaceuticals gained access to Alimera’s two commercial products that treat diabetic macular edema (DME) and chronic non-infectious uveitis. This acquisition bolstered ANI Pharmaceuticals, Inc.’s presence in the ophthalmic therapeutics market.
   

Uveitis Treatment Market Companies

Some of the eminent market participants operating in the uveitis treatment industry include:

• AbbVie
• Alimera Sciences
• Bausch Health Companies
• Clearside Biomedical
• EyePoint Pharmaceuticals
• Novartis
• Pfizer
• Santen Pharmaceutical
   

The uveitis treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Corticosteroids
• Immunosuppressants/Immunomodulators
• Biologics
• Cycloplegic agents
• Analgesics
• Other treatments

Market, By Disease Type

• Anterior uveitis
• Posterior uveitis
• Intermediate uveitis
• Panuveitis

Market, By Route of Administration

• Oral
• Topical
• Injectable

Market, By Disease Etiology

• Infectious
• Non-infectious

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• E-commerce
• Other distribution channels

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE